Scripps Health Secures $12.7M Grant for Stem Cell-Based Knee Repair Research
Event summary
- Scripps Health received a $12.7 million grant from CIRM for preclinical studies on stem cell-based knee repair.
- The five-year grant will fund tissue engineering and cartilage/bone injury repair surgeries in animal models.
- Researchers aim to submit an IND application to the FDA by the end of the grant period for potential human trials.
- The grant also supports regulatory work, clinical protocol development, and patient access planning.
- Scaffold-free tissue engineering technology was developed by Scripps senior staff scientist Shawn Grogan.
The big picture
Scripps Health's grant underscores the growing investment in regenerative medicine, particularly for orthopedic applications. The research addresses critical limitations in current treatments, such as donor tissue availability and scaffold-based implant challenges. If successful, this approach could significantly delay or eliminate the need for joint replacements, a $12 billion global market. The strategic focus on scaffold-free tissue engineering positions Scripps at the forefront of orthopedic innovation.
What we're watching
- Regulatory Approval
- Whether Scripps can successfully navigate the FDA approval process for its IND application.
- Clinical Translation
- The pace at which preclinical findings can be translated into effective human treatments.
- Market Adoption
- How the potential affordability and accessibility of the treatment will impact patient adoption.
Related topics